Form 4: Cytokinetics EVP Fady Ibraham Malik Reports Stock Transactions

Fady Ibraham Malik, EVP of Research & Development at Cytokinetics, reports the acquisition and disposal of Cytokinetics common stock and derivative securities on August 20, 2024.

Summary

• On August 20, 2024, Fady Ibraham Malik, EVP of Research & Development at Cytokinetics, reported transactions involving Cytokinetics Inc. common stock.
• Malik disposed of 2,000 shares of common stock at a price of $56.23 per share.
• He also acquired 5,300 shares of common stock through the exercise of non-qualified stock options at a price of $7.96 per share.
• Simultaneously, Malik disposed of 5,300 shares of common stock at $56.26 per share.
• Following these transactions, Malik beneficially owns 125,004 shares of common stock directly.
• He also owns 42,400 non-qualified stock options.

Sentiment

Score: 5

Explanation: This is a neutral report of stock transactions, with no inherent positive or negative sentiment.

Industry Context

This Form 4 filing is a routine disclosure of stock transactions by a company insider, as required by the SEC. It provides transparency into the trading activities of key personnel and their holdings in the company.

Stakeholder Impact

• The transactions may be of interest to shareholders as they provide insight into the executive's perspective on the company's stock.

Key Dates